Document Type
Article Presentation
Original Publication Date
2021
Date of Submission
April 2021
Abstract
This presentation is on the effect of different dosages of fenretinide on children with neuroblastoma. Neuroblastomas are the second most common malignant tumor growth in children with a high fatal relapse rate. Children diagnosed with this disease have less than a 50% chance of survival within five years of diagnosis. Fenretinid and other retinoids have been extensively studied in vitro, but this article highlights phase I where the safest and most effective dosages lie. Patients' eligibility was based on a list of guidelines, and patients were given the drug for 28 days followed by a seven-day interruption in a cycle. Results determined that the 1000 mg/ m2/day or higher lead to favorable effects. Manageable side effects occurred as a result of this medication. Phase II of this drug trial would be warranted.
Rights
© The Author(s)
